CD8A and Alzheimer disease: In AD mouse models including 5xFAD mice, the surrogate effect markers of previous findings/trials of systemic or intraventricular administration of CD8 + T cells [31], anti-CD8 [32] or anti-CD3 [33] antibodies, Treg cells [34–36] (or for stroke model [37] or DEREG model for traumatic brain injury model [38]), and amyloid-sensitized Th1 cells [39–41] were amyloid plaques/Aβ on immunohistochemistry and transcriptional signatures of major brain cells and brain parenchyma [32, 33, 35] or CP infiltrating cells [25, 42].